In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in vitro validation against murine coronavirus

2026/08/01 by Nina Kobe, Lennart Dreisewerd, Miha Lukšič +14

paper · doi:10.1016/j.bioorg.2026.109949

crossref created 2026/05/06 · crossref deposited 2026/07/03 · crossref issued 2026/08/01 · crossref published 2026/08/01 · crossref published-print 2026/08/01 · crossref indexed 2026/08/04

Citations

• Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers
• Coronavirus envelope protein: current knowledge
• Molecular Evolution of Human Coronavirus Genomes
• Surveillance of Resistance to Adamantanes among Influenza A(H3N2) and A(H1N1) Viruses Isolated Worldwide
• Systematic Assembly of a Full-Length Infectious cDNA of Mouse Hepatitis Virus Strain A59
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12